Attached files
Exhibit 31.1
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002
I, Alan
W. Schoenbart, certify that:
1. I have reviewed
this Quarterly Report on Form 10-Q of Echo Therapeutics, Inc. (the
“Company”) for the quarter ended September 30,
2016;
2.
Based on my
knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material factnecessary to make the
statements made, in light of the circumstances under which such
statements were made, notmisleading with respect to the period
covered by this report;
3.
Based on my
knowledge, the financial statements, and other financial
information included in this report, fairly present inall material
respects the financial condition, results of operations and cash
flows of the Company as of and for the periodspresented in this
report;
4.
The Company’s
other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the Company and have:
(a)
Designed such
disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the Company, including
its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period on which this report
is being prepared;
(b)
Designed such
internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;
(c)
Evaluated the
effectiveness of the Company’s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures as of the
end of the period covered by this report based on such evaluation;
and
(d)
Disclosed in this
report any change in the Company’s internal control over
financial reporting that occurred during the Company’s most
recent fiscal quarter that has materially affected, or is
reasonably likely to materially affect, the Company’s
internal control over financial reporting; and
5.
The Company’s
other certifying officer and I have disclosed, based on our most
recent evaluation of internal control overfinancial reporting, to
the Company’s auditors and the audit committee of the
Company’s Board of Directors:
(a)
All significant
deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably
likely to adversely affect the Company’s ability to record,
process, summarize and report financial information;
and
(b)
Any fraud, whether
or not material, that involves Management or other employees who
have a significant role in the Company’s internal control
over financial reporting.
Date:
November 16, 2016
/s/ Alan W.
Schoenbart
Alan W.
Schoenbart
Chief
Financial Officer
(Principal
Executive Officer)